Purpose: Evaluation of vascular disruptive activity in orthotopic models as potential surrogate biomarkers of tumor response to the microtubule-stabilizing agent patupilone.

Experimental Design: Mice bearing metastatic B16/BL6 melanoma and rats bearing mammary BN472 tumors received vehicle or efficacious patupilone doses (4 and 0.8-1.5 mg/kg i.v., respectively). Tumor vascularity assessment by dynamic contrast-enhanced or dynamic susceptibility contrast magnetic resonance imaging and interstitial fluid pressure (IFP) occurred at baseline, 2 days (mice and rats), and 6 days (rats) after treatment and were compared with histologic measurements and correlated with tumor response.

Results: In B16/BL6 metastases, patupilone (4 mg/kg) induced a 21 ± 5% decrease (P < 0.001) in tumor blood volume and a 32 ± 15% decrease (P = 0.02) in IFP after 2 days and reduced tumor growth and vessel density (>42%) after 2 weeks (P ≤ 0.014). Patupilone dose-dependently inhibited BN472 tumor growth (day 6) and reduced IFP on days 2 and 6 (−21% to −70%), and the percentage change in IFP correlated (P < 0.01) with the change in tumor volume. In both models, histology and vascular casts confirmed decreases in tumor blood volume. One patupilone (0.8 mg/kg) administration decreased (P < 0.01) tumor IFP (54 ± 4%), tumor blood volume (50 ± 6%), and vessel diameter (40 ± 11%) by day 6 but not the apparent diffusion coefficient, whereas histology showed that apoptosis was increased 2.4-fold and necrosis was unchanged. Apoptosis correlated negatively (P < 0.001) with IFP, tumor blood volume, and tumor volume, whereas tumor blood volume and IFP were correlated positively (P = 0.0005).

Conclusions: Vascular disruptive effects of patupilone were detected in situ using dynamic contrast-enhanced or dynamic susceptibility contrast magnetic resonance imaging and IFP. Changes in IFP preceded and correlated with tumor response, suggesting that IFP may be a surrogate biomarker for patupilone efficacy.

Patupilone, also known as epothilone B (EPO906), is a potent microtubule stabilizer. Epothilones, which are secondary metabolite macrolides produced by the myxobacterium Sorangium cellulosum (1), represent a novel class of nontaxane microtubule-stabilizing natural products. Although patupilone has the same molecular target as the taxanes, it binds β-tubulin with a higher affinity (2) and the binding sites are probably not identical (3). Binding promotes polymerization of tubulin heterodimers into microtubule polymers and stabilizes microtubules against depolymerization, resulting in mitotic cell cycle arrest and eventually cell death via apoptosis (46). In non–small cell lung cancer cells, apoptosis due to patupilone exposure seems to be cathepsin B dependent (7). Preclinical work has shown that patupilone is the most active variant among the natural epothilones, is more potent than the taxanes, and, most importantly, retains activity in vitro and in vivo against taxane-resistant cancer cells overexpressing P-glycoprotein or bearing β-tubulin mutations (46, 8). Additionally, as a tubulin-binding agent, patupilone should show antivascular effects by disrupting rapidly proliferating and immature endothelial cells, which have a particularly strong dependence on tubulin to maintain their shape (9). Support for this hypothesis was recently provided with cultured cells using low doses of patupilone (10) and on clinical tumor explants (11). Inhibition of endothelial cell function could also have a negative effect on the metastatic process. Thus, both this compound class and the target are considered to have great potential for the treatment of cancer (6, 12).

Patupilone shows marked activity against solid human tumor xenografts grown in nude mice, including thyroid (13), lung, breast, colon, and prostate (4), when given at 3 to 4 mg/kg as an i.v. bolus on a weekly schedule (4, 14). The drug displays a rapid t1/2α, is eliminated from plasma with a terminal half-life of ∼6 hours, and shows a large volume of distribution to all tissues, including the tumor xenografts and brain from which tissues it is eliminated more slowly (15). Dose-dependent activity against s.c. grown rat C6 glioma tumors has also been shown, and in this model and a human thyroid carcinoma xenograft model, there was synergy when combined with the novel anticancer agent imatinib (13, 16). In summary, the pharmacokinetic profile and activity of patupilone in experimental tumor models suggest that it could be an effective treatment for a range of solid tumors in the clinic. Patupilone is currently in clinical development and early phase II data indicate promising activity in several different solid tumor indications (12, 14). However, a convenient and predictive surrogate biomarker of patupilone is currently not available because the pharmacokinetic profile limits the possibility of using drug levels in the plasma to obtain an effective pharmacokinetic/pharmacodynamic relationship.

The initial growth of a solid tumor is amid normal tissue where it makes use of existing vasculature. Further growth requires formation of new blood vessels (i.e., angiogenesis), but generally these blood vessels tend to be leaky, highly irregular, and tortuous, exhibit arteriovenous shunts and blind ends, and have a sluggish flow due to the high viscosity of the blood (17, 18). The tumor is also unable to form its own lymphatic system, so that solutes cannot be efficiently drained from the tumor interstitial space. Furthermore, the blood vessels are compressed by proliferating cells and this increases the microvascular pressure. Together, these factors contribute to an elevated interstitial fluid pressure (IFP) in solid tumors compared with normal tissues (17). In experimental tumor models, the IFP was found to be uniform across the whole tumor, except at the periphery where it dropped precipitously (17). Jain (17) predicted that the high IFP would reduce movement of molecules from blood vessels to the interstitial space, particularly large molecules (>5 kDa), which move more by convection than diffusion and thus may be a major barrier to the delivery of larger chemotherapeutics. However, recent data suggest that relatively small chemotherapeutics, such as 5-fluorouracil, paclitaxel, and patupilone, also show increased uptake into experimental tumors when the IFP is lowered pharmacologically (13, 19, 20). Thus, there is considerable interest in understanding better the causes of a high tumor IFP to find means to reduce it and elevate drug uptake. Preclinically, although many groups have shown that drugs can lower the IFP of solid tumors, including prostaglandin E1 (19), dexamethasone (21), imatinib (22), and paclitaxel (23), it has not been investigated whether this effect might also be a predictive factor for drug response. Although Lee et al. (24) showed that an anti–vascular endothelial growth factor antibody lowered the IFP of human tumor xenografts and decreased tumor growth, this was not done by measuring tumor growth and IFP in the same animals; furthermore, there are no investigations of this type for cytotoxics. IFP has also been measured in the clinic in several different solid tumors, including breast, cervix, head and neck, liver metastases, kidney, lung, and melanoma, and found to be always greater than zero, which is the value for normal tissue (17). In one study, IFP was used as a prognostic factor and this showed that it was the single best indicator of survival for patients with cancer of the cervix where a high IFP was associated with a poor prognosis (25). More recently, it has been shown that Avastin, the vascular endothelial growth factor A antibody, and paclitaxel could lower the IFP of renal and breast tumors, respectively (26, 27). A demonstration of a correlation between changes in tumor growth and IFP in the same tumor would suggest that IFP could be used as a surrogate biomarker of response.

Identifying potential responders is critical to successful drug treatment of patients, and development of biomarkers should be an aid to the Response Evaluation Criteria in Solid Tumors, which can be relatively inaccurate and subjective (28). In any case, Response Evaluation Criteria in Solid Tumors may not predict progression-free survival or overall survival, which in some cases can be better predicted by a biomarker (29, 30). Biomarkers can include proteins circulating in the serum, such CA-125, molecular analysis of expression from biopsies, as well as variables supplied by various noninvasive functional imaging modalities, such as [18F]fluoro-2-deoxy-d-glucose positron emission tomography or dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI; ref. 31). The latter has been proven useful in the development of antiangiogenic drugs where changes in the tumor vasculature can be a marker of whether the effective dose has been reached as well as tumor response (32).

The aim of this study was to investigate the effects of patupilone on the vasculature of solid tumors using a variety of different techniques, including methods that were noninvasive, using DCE-MRI or dynamic susceptibility contrast MRI (DSC-MRI), minimally invasive (IFP measurement) and invasive using histology ex vivo. For this, we have used two orthotopic and syngeneic rodent models, so that the target, the endothelial cells in the vascular supply, would be more prevalent and thus more likely to resemble tumors in patients. This approach could help identify an independent surrogate biomarker of response using a method(s) that can be applied in the clinic and would thus aid development of patupilone.

### Animals

All animal experiments were done in strict adherence to the Swiss law for animal protection. Animals were identified by tail markings and kept in groups of 4 to 10 animals under normal conditions with access to food and water ad libitum. Female black C57/BL6 syngeneic mice weighing 20 to 25 g were obtained from Charles River (Lyon, France). Female Brown-Norway rats weighing 160 to 180 g were obtained from Charles River. The Brown-Norway rats had a mild, apparently noninfectious pneumonia in the lungs (defined pathologically as multifocal granulomatous pneumonia), which did not affect their general health but precluded studies of metastasis. Except where stated, all animals were sacrificed by CO2 inhalation.

### Materials

All cell culture materials were obtained from Life Technologies (Paisley, United Kingdom) or BioConcept (Allschwil, Switzerland). Gadolinium 1,4,7,10-tetra-azacylododecane N,N′,N″,N‴,-tetra-acetate (GdDOTA; Dotarem), the extravascular contrast agent, and Endorem and Sinerem (dextran-coated iron oxide nanoparticles) the intravascular contrast agents, were obtained from Guerbet SA (Roissy, France).

### Drug preparation and treatment

Patupilone was obtained from Chemical Development, Novartis (Basel, Switzerland) and the powder was stored at −20°C. It was freshly prepared on each treatment day by dissolving in polyethylene glycol 300 and then diluting with physiologic saline [0.9% (w/v) NaCl] to obtain a mixture of 30% (v/v) polyethylene glycol 300 and 70% (v/v) physiologic saline for i.v. administration in the tail vein. The injection volume was 2 and 5 mL/kg for rats and mice, respectively. Treatment with vehicle or patupilone was normally once only or once weekly in the efficacy studies.

### Tumor models: efficacy and toxicity

Where possible, tumor growth and body weights were monitored at least twice weekly. Toxicity was determined by the percentage change in body weight versus those recorded in the vehicle-treated controls. No other obvious toxicity was observed in mice (e.g., diarrhea; the dose-limiting toxicity observed in clinical trials), although some diarrhea was observed in Brown-Norway rats at the highest patupilone doses tested at 3 to 5 days after injection.

Mouse B16/BL6 metastatic melanoma. Cells were cultured in MEM supplemented with 2 mmol/L glutamine, 5% FCS, 1% sodium pyruvate, 1% nonessential amino acids, and 2% vitamins and kept at confluence for 4 to 5 days (with a medium change every 48 hours) before resuspension in HBSS (+10% FCS). Using a Hamilton syringe, 5 × 104 cells were injected i.d. in a volume of 1 μL into the dorsal pinna of both ears of the anesthetized mouse as described previously (33). After 1 week, the primary tumor was visible as a black dot in the middle of the ear, and after 10 days, the cervical lymph node metastases were detectable by palpitation and were used for all biomarker studies from 14 days after cell inoculation.

Mice were randomized into three groups of six mice per group and treatment with vehicle or patupilone (2 or 4 mg/kg) was once weekly for 2 weeks beginning 7 days after cell inoculation. For primary tumors, growth was assessed by the fractional change in tumor surface area compared with the area at the initiation of treatment. Efficacy was expressed as a treated versus control (T/C; i.e., mean fractional increase of drug-treated mice divided by mean fractional increase of vehicle-treated mice). For the metastases, the mice were sacrificed at the end of the treatment period, the lymph nodes were removed and weighed, and the T/C was determined from the mean volume of the metastases from the drug-treated mice divided by the mean volume of the metastases from the vehicle-treated mice.

Rat BN472 mammary carcinoma. BN472 tumors were created by transplantation of tumor fragments. Tissue frozen at −180°C from earlier in-house studies was washed sterilely in 0.9% NaCl containing 100 μg/mL gentamicin and then placed in a Petri dish containing Ham's F-12 medium with 100 μg/mL gentamicin and 10% FCS. The tumor tissue was divided into small pieces (3 × 3 × 3 mm) and one piece was inserted into a hole made by a 22-gauge sterile needle in the lowest mammary fat pad of anesthetized rats after wiping the skin with 70% alcohol. The hole was closed with two metal wound clips, which were then removed after 3 to 4 days. Tumors were used for efficacy and biomarker studies at 2 to 3 weeks after transplantation.

Rats were randomized into different treatment groups and treated with vehicle or various doses of patupilone (0.3, 0.8, 1, and 1.5 mg/kg once). Efficacy was assessed after 1 week as a T/C determined from the mean change in tumor volume (TVol) (determined from the formula: l * w * h * π / 6) of drug-treated rats divided by the mean change in volume of vehicle-treated rats.

### Magnetic resonance imaging

MRI was done on mouse B16/BL6 cervical lymph node metastases and rat BN472 mammary tumors. For all studies, animals were anaesthetized using 1.5% isoflurane (Abbott, Cham, Switzerland) in a 1:2 (v/v) mixture of O2/N2O and placed on an electrically warmed pad for cannulation of one of the tail veins using a 30-gauge needle attached to an infusion line of 30 cm and volume of 80 μL to permit remote administration of the contrast agent. The animals were positioned on a cradle in a supine position inside the 30-cm horizontal bore magnet and were anesthetized with 1.5% isoflurane in a 1:2 (v/v) mixture of O2/N2O given with a facemask (flow rate, 0.7 L/min). The mouse body temperature was maintained at 37 ± 2°C using a warm air flow and was monitored with a rectal probe. MRI experiments were done on a Bruker DBX 47/30 spectrometer (Bruker BioSpin, Fällanden, Switzerland) at 4.7 Tesla equipped with a self-shielded 12-cm bore gradient system as described previously (33).

Dynamic contrast-enhanced magnetic resonance imaging. In mice, the contrast agent GdDOTA was injected (0.1 mmol/kg) for determination of tumor vascular permeability (initial slope of GdDOTA uptake) and extravasion [i.e., tumor extracellular leakage space (final value for GdDOTA uptake)], and the first 20 points (102 seconds) from the injection of GdDOTA were used to calculate the initial area under the enhancement curve (IAUC) for GdDOTA. After 15 minutes, the iron oxide particle intravascular contrast agent Endorem was injected (6 mmol/kg iron) for determination of the relative tumor blood volume (rBVol), and the initial slope of uptake of Endorem by the tumor was used as an index of blood flow (BFI). The principles behind measurement of these variables have already been fully described (33). Animals were examined at baseline (day 0) before treatment with vehicle or patupilone, and at days 2 and/or 6, repeat DCE-MRI scans were made. The results were then expressed as the individual and mean change compared with baseline (day 0) measurement.

Dynamic susceptibility contrast magnetic resonance imaging. In rats bearing BN472 tumors, the contrast agent Sinerem, which is also an iron oxide particle intravascular contrast agent, was injected i.v. (0.2 mmol/kg iron) for measurement of tumor vessel size imaging (VSI) and absolute BVol as a percentage of the total tumor size (BVol). Briefly, the method is based on the measurement ΔR2 and ΔR2* relaxation rate constants induced by the injection of an intravascular slow clearance superparamagnetic contrast agent, such as Sinerem. Based on relaxation theory, it was shown in vivo that the ratio ΔR2*/ΔR2 is related to the diameter of the vessels (34). R2* is determined directly by a multigradient recalled echo sequence (TR 400 ms, TE 3-24 ms, 8 echoes) before and after contrast agent infusion. ΔR2, on the other hand, is assessed by the acquisition of T2-weighted MRIs (repetition time 4,000 ms, echo time 18 ms) before and after contrast agent infusion. It is calculated according to (34)

$\mathit{{\Delta}R}_{\mathrm{2}}\ =\ \frac{\mathrm{1}}{\mathit{T_{E}}}\mathrm{ln}\left(\frac{\mathit{S}_{\mathrm{pre}}}{\mathit{S}_{\mathrm{post}}}\right),$

where Spre and Spost are the signal intensities before and after Sinerem infusion, respectively.

Mean vessel diameter R is calculated according to the following equation (35):

$\mathit{R}\ =\ \mathrm{0.425}\left(\frac{\mathit{D}}{\mathit{{\gamma}{\Delta}}\mathrm{{\chi}}\mathit{B}_{\mathrm{0}}}\right)^{\mathrm{1/2}}\left(\frac{\mathit{{\Delta}R}_{\mathrm{2}}^{*}}{\mathit{{\Delta}R}_{\mathrm{2}}}\right)^{\mathrm{3/2},}$

where D is the water diffusion coefficient in tumor tissue, γ is the gyromagnetic constant of the proton, Δχ is the susceptibility difference between blood vessels and the surrounding tissues induced by the contrast agent, and B0 is the magnetic field strength of the magnet.

Blood fraction ξ0 (BVol) can be derived according to the equation:

$\mathit{{\xi}}_{\mathrm{0}}\ =\ \frac{\mathrm{3}}{\mathrm{4{\pi}}}\frac{\mathit{{\Delta}R}_{\mathrm{2}}^{*}}{\mathit{{\gamma}{\Delta}}\mathrm{{\chi}}\mathit{B}_{\mathrm{0}}}$

and is expressed as a percentage of the total TVol.

The water diffusion coefficient (D) was calculated as follows. Diffusion-weighted images were acquired using a spin-echo sequence with the following variables: repetition time 1,000 ms, echo time 22.5 ms, field of view 70 mm (rat) or 40 mm (mice), matrix 128 × 64 (acquisition) and 1282 (reconstruction), slice thickness 1.5 mm, numerical aperture 2, spectral width 50 kHz, and total acquisition time 8 minutes 32 seconds. Four diffusion weighting acquisitions were done with b-factors 18.3, 43.9, 131.4, and 450.5 seconds/mm2 (rats) or 31.5, 62.9, 161.8, and 503.9 seconds/mm2 (mice) in read direction. Diffusion time (Δ) was 25 ms and diffusion gradient duration (δ) was 5 ms.

The apparent diffusion coefficient (ADC) maps were calculated by pixel-wise nonlinear fitting procedures of the four diffusion-weighted images by the imager software (ParaVision, Bruker BioSpin) according to the model function:

$\mathit{S}_{\mathrm{b}}\ =\ \mathit{S}\mathrm{_{0}*e}^{{-}\mathit{b*}\mathrm{ADC,}}$

where Sb and S0 are the signal intensities with and without diffusion gradients, respectively, and b is the diffusion weighting defined by the diffusion gradient strengths and timings. Diffusion weighting factor b is given by the formula:

$\mathit{b}\ =\ \mathit{{\gamma}}^{\mathrm{2}}\mathit{g}^{\mathrm{2}}\mathit{{\delta}}^{\mathrm{2}}\left(\mathrm{{\Delta}}\ {-}\ \frac{\mathit{{\delta}}}{\mathrm{3}}\right),$

where g is the diffusion gradient strength, δ is the diffusion gradient duration, and Δ is the diffusion time.

ADC values are given as the mean of the regions of interest encompassing the entire tumor.

### Tumor interstitial fluid pressure

The IFP of B16/BL6 and BN472 tumors was measured using the wick-in-needle method as described previously (13). Briefly, animals were divided into different treatment groups and anesthetized using 2.5% isoflurane delivered at 2 L/min. A standard 23-gauge needle connected to a pressure transducer was inserted into the central part of the tumors, and the pressure was monitored for a period of 10 minutes. Animals were then treated with vehicle or patupilone, and the IFP was monitored again at 2 and 6 days later. Results are expressed as the individual and mean change compared with baseline (day 0) measurement.

In the rat BN472 tumors, repeated measurements were readily made, and consistent with earlier reports in other experimental tumors (17), the IFP was found to be invariable across the tumor, except at the periphery. Furthermore, the IFP was independent of BN472 TVol over the range studied of 0.1 to 4 cm3 (data not shown).

### Histologic methods

H33342 staining of functional blood vessels. The nuclear staining dye, H33342 (Sigma, Buchs, Switzerland) was injected i.v. at 20 mg/kg (2 mg/mL in normal saline) into anesthetized animals, and after 45 seconds, the animals were sacrificed under anesthesia by cervical dislocation and the tumor was removed. The tumor was sliced through the central plain and analyzed as described previously (33) using a magnification of ×100 to determine the blood vessel width and density number. To display the frequency distribution of blood vessel width, vessels were assigned to groups of 10-μm size range (external diameter).

Apoptosis (caspase-3 staining) and necrosis. Following treatment and noninvasive biomarker measurements (day 6), the rats were sacrificed. Tumor slices were harvested from the largest circumference of the tumor, fixed in 4% phosphate-buffered formaldehyde for 24 hours at 4°C, and processed into paraffin. The skin overlying the tumor was swabbed with 70% ethanol, and using surgical scissors, spindle-shaped cuts were made to isolate the tumor ensuring that the superficial skin remained attached. The tumor mass was removed en bloc to a dissection tray and the tumor was cut into equal pieces using a scalpel (no. 10 curved blade). Tumor pieces were not allowed to exceed 3 to 4 mm in thickness, and care was taken to leave the overlying skin attached to the tumor where possible. Tumor pieces were transferred into prelabeled histocasettes and then immersion fixed in 4% phosphate-buffered formaldehyde (pH 7.4; J.T. Baker, Medite, Nunnigen, Switzerland) at 4°C for ≤24 hours. At least 10 times more fixative volume than tissue volume was used.

After fixation, tissue samples were rinsed in 70% ethanol and immediately processed into paraffin using the Wochenprogramm (run time, 10.5 hours) on the TPCduo tissue processor (Medite). After paraffinization, tissue samples were embedded in paraffin. From each tissue block, 3-μm-thick serial sections were cut on a Mikrom sliding microtome (Medite), spread on a 37°C water bath, mounted on microscope slides (Polysine, Menzel, Medite), and air dried at 37°C overnight. One tissue section was stained with H&E on the COT20 linear stainer (Medite). The remaining serial sections were either immediately used for immunohistochemistry or stored at −80°C until used (see below).

Tissue sections were deparaffinized in two changes of fresh xylene for 20 minutes at room temperature followed by hydration of tissue sections in absolute ethanol for 10 minutes, in 96% ethanol for 10 minutes, in 70% ethanol for several rinses, and in PBS (pH 7.4) without Ca2+ and Mg2+ for 2 × 5 minutes. Heat-induced antigen retrieval was done in 20 mmol/L boric acid buffer (pH 7.0) for 10 minutes at 98°C using a temperature-controlled microwave (Micromed T/T Mega, Medite). Sections were allowed to cool for 20 minutes and were washed in PBS for 2 × 5 minutes. The endogenous peroxidase was blocked with freshly prepared 3.0% H2O2 in methanol for 10 minutes followed by rinsing in PBS for 2 × 5 minutes. Tissue sections were blocked by incubation with 10% normal goat serum in PBS for 30 minutes.

For immunohistochemical detection of active caspase-3, a rabbit anti-cleaved caspase-3 (Asp175) antibody (9661, Cell Signaling, BioConcept) was used. The primary antibody was applied in a dilution of 1:50 in 10% normal goat serum and incubated overnight at 4°C. Tissue sections were rinsed in PBS for 2 × 5 minutes and incubated with DAKO EnVision+ rabbit (K4003, DAKO, Geneva, Switzerland) for 30 minutes at room temperature. Tissue sections were rinsed in PBS for 2 × 5 minutes and incubated with freshly prepared AEC substrate solution (AEC tablets, Sigma) for 11 minutes. The reaction was stopped by rinsing tissue sections in tap water, and counterstaining was done in hematoxylin (Mayer's hematoxylin, Medite) for 30 seconds. Tissue sections were blued in tap water, coverslipped with water-soluble mounting medium (Aquatex, Merck, Glattbrug, Switzerland), and air dried.

Active caspase-3 immunohistochemistry was done on tissue sections from all collected samples. Stained tumor sections were coded such that the evaluator was unaware from which treatment group the samples were obtained. Tumor sections were evaluated for active caspase-3-positive tumor cells using a E800M Nikon microscope. A grid integrated into the ×10 ocular high-power fields composed of 10 × 10 squares (100 files total) encompassing an area of 250 × 250 μm at × 400 magnification was used for quantification of caspase-3 activity. The content of 10 grids was calculated. Active caspase-3-positive particles were calculated in grids containing viable tumor cells. Necrotic areas or border of necrotic areas were excluded from quantification. Care was taken to randomly select tissue areas and not to include adjacent tissue areas to areas that were already counted. The amount of necrotic tumor present was estimated and expressed as percentage of the total area.

### Vascular casts

Mice were thoracectomized after having been deeply anesthetized with 3% isoflurane (20 L/min) and perfused through the left ventricle of the heart. The left ventricle was punctured with a 19- or 23-gauge needle (for rats and mice, respectively) from a winged infusion set (SV-19BLK; Termudo, Elkton, MD), which was connected to an airtight pressurized syringe containing the rinsing solution (NaCl 0.9% with 250,000 units/L heparin at 35°C). The right atrium was punctured to provide outflow, and the perfusate was infused under a precise controlled pressure of 120 mm Hg. The perfusion was continued for 2 or 5 minutes (for mice and rats, respectively) at a constant rate (20 mL) followed by a prefixation solution (2% performaldehyde in PBS at 35°C). Finally, up to 10 to 30 mL polyurethane resin (PUII4; Vasqtec, Zurich, Switzerland) was infused at the same rate.

The resin-filled tumor was excised from the animal and kept at room temperature for 48 hours to complete resin curing. The tumor cast was then weighed and the soft tissue was removed by maceration in 7.5% KOH during 24 hours at 50°C. The casts were then thoroughly cleaned with and stored in distilled water before drying by lyophilization. Casts were semiquantified by determination of the vascular index (percentage of vascularized tissue), which was calculated from the ratio of the weight before and after KOH extraction.

### Statistical methods

All results show the mean ± SE. A significant change in TVol compared with vehicle treatment was assessed using a two-tailed t test or one-way ANOVA applying the Holms-Sidak test post hoc for multiple comparisons on the ΔTVol. For biomarker studies, the individual values for each animal are shown both before and one or two time points after treatment, so that the intertumor variability of the response is clearer. A statistically significant change (P < 0.05) in the biomarkers measured in situ (IFP, BVol, ADC, and VSI) compared with baseline was assessed using a paired t test for two time points or a one-way ANOVA with repeated measures applying the Holms-Sidak test post hoc for three time points (using the software from SigmaStat version 3.1). A two-tailed t test was used to compare mean percentage changes between different treatment groups. Correlations between different variables were made by determining Pearson correlation coefficient, with P < 0.05 considered as significant. Where multiple correlations were made between the different variables measured in vivo and ex vivo in the data set of BN472 tumors treated with vehicle or a dose of 0.8 mg/kg patupilone, a Bonferroni correction was made (P multiplied by the number of correlations). In this particular data set, one rat was excluded from all analyses because it was an outlier by Grubb's test (also called the extreme studentized deviate method; see http://www.graphpad.com) for the magnetic resonance–determined values of BVol, ADC, and VSI. For determination of the significance of the association Δ%IFP with tumor response, Fisher's exact test was applied to a 2 × 2 contingency table. The cutoffs for this analysis were based on the decrease in tumor IFP observed in vehicle-treated rats (9 of 10 in the range of −1% to −35%) and response was defined as a ΔTVol less than or equal to 1 SD from the mean of the vehicle-treated rats (1.8 cm3 minus 1.3 cm3).

Effect of 2-week patupilone treatment in the B16/BL6 mouse melanoma model. In two independent experiments, patupilone dosed weekly induced dose-dependent inhibition of growth of both primary tumor and cervical lymph node metastases of B16/BL6 mouse melanoma cells orthotopically implanted into C57BL6 mice. Figure 1A and B shows one experiment, in which the 2 mg/kg dose significantly reduced primary tumor growth (T/C, 26%) but not the cervical metastases (T/C, 123%), whereas the higher dose (4 mg/kg) significantly reduced growth of both tumors compared with vehicle-treated mice (P < 0.001). In cervical metastases, vessel density was significantly reduced (P = 0.014) compared with vehicle-treated controls metastases by 40%, and the frequency distribution of blood vessel widths revealed a higher frequency of larger vessels after treatment with patupilone (Fig. 1C). The occurrence of lung metastases (animals scoring positive for the presence of lung metastases) in the vehicle-treated groups was ∼40% and 70% in the two experiments, whereas it was 0% in the groups receiving 4 mg/kg. Patupilone was well tolerated, with no obvious effects on the well-being or behavior of the mice at either treatment dose in comparison with vehicle-treated controls.

Fig. 1.

Effect of patupilone on B16/BL6 melanoma primary tumors and cervical lymph node metastases after 2 weeks. B16/BL6 cells (5 × 104) were injected i.d. in both ears of C57BL/6 mice. Weekly treatment with patupilone (2 or 4 mg/kg i.v.) or vehicle was initiated 7 days after cell inoculation and continued until day 21. Points, mean (A) primary tumor growth and (B) cervical metastases weight after 21 days; bars, SE. **, P < 0.001; *, P = 0.003, significantly different compared with the vehicle-treated control on day 21 (one-way ANOVA applying the Holms-Sidak test post hoc). C, frequency distribution of blood vessel diameters in the cervical metastases at day 21 following treatment with vehicle or the 4 mg/kg dose of patupilone. The mean ± SE vessel density was 11.9 ± 1.0 and 7.2 ± 1.2 μm for the vehicle and patupilone groups, respectively. P = 0.014 (two-tailed t test).

Fig. 1.

Effect of patupilone on B16/BL6 melanoma primary tumors and cervical lymph node metastases after 2 weeks. B16/BL6 cells (5 × 104) were injected i.d. in both ears of C57BL/6 mice. Weekly treatment with patupilone (2 or 4 mg/kg i.v.) or vehicle was initiated 7 days after cell inoculation and continued until day 21. Points, mean (A) primary tumor growth and (B) cervical metastases weight after 21 days; bars, SE. **, P < 0.001; *, P = 0.003, significantly different compared with the vehicle-treated control on day 21 (one-way ANOVA applying the Holms-Sidak test post hoc). C, frequency distribution of blood vessel diameters in the cervical metastases at day 21 following treatment with vehicle or the 4 mg/kg dose of patupilone. The mean ± SE vessel density was 11.9 ± 1.0 and 7.2 ± 1.2 μm for the vehicle and patupilone groups, respectively. P = 0.014 (two-tailed t test).

Close modal

Effect of acute patupilone treatment on vascularity and interstitial fluid pressure of B16/BL6 metastases. The effect of a single dose of 4 mg/kg patupilone on the vascularity of cervical metastases was investigated noninvasively using DCE-MRI to assess vessel permeability (initial slope of GdDOTA uptake), extracellular leakage space (final value for GdDOTA uptake), BFI, and rBVol. Well-established metastases (>14 days old) were examined both before and 2 days after treatment with patupilone or vehicle to allow determination of changes in individual animals. No significant effects of patupilone could be determined on the DCE-MRI measured variables of initial slope of GdDOTA uptake, final value for GdDOTA uptake (IAUC) or BFI compared with vehicle: the fractional changes for patupilone treatment relative to vehicle treatment were 0.94, 1.09, 1.03, and 1.0 for the respective variables. However, most patupilone-treated mice (18 of 22) showed a decrease in rBVol, and compared with baseline, this was highly significant (P = 0.0005; −21 ± 5%), whereas in the vehicle-treated group there was no significant change (−7 ± 6%; see Fig. 2A). The difference between the mean percentage change between the two groups did not reach significance (P = 0.092, two-tailed t test). Representative rBVol maps are shown for one lymph node tumor before and after patupilone treatment (Fig. 2B and C).

Fig. 2.

Effect of 4 mg/kg patupilone on rBVol and IFP of B16/BL6 cervical lymph node metastases after 2 days. B16/BL6 cells (5 × 104) were injected i.d. in both ears of C57BL/6 mice. After 2 to 3 weeks, the contrast agent Endorem was injected i.v. and rBVol was determined using DCE-MRI followed by the WIN method for IFP both before (day 0) and after (day 2) treatment with vehicle or patupilone (4 mg/kg i.v. bolus once). Individual values from each tumor. Points, mean before and after treatment for (A) rBVol and (D) IFP; bars, SE. **, P = 0.0005; *, P = 0.02, compared with baseline (two-tailed paired t test). A rBVol map is shown for a representative lymph node tumor before (B) and after (C) patupilone treatment, where the change in rBVol was calculated to be −38%.

Fig. 2.

Effect of 4 mg/kg patupilone on rBVol and IFP of B16/BL6 cervical lymph node metastases after 2 days. B16/BL6 cells (5 × 104) were injected i.d. in both ears of C57BL/6 mice. After 2 to 3 weeks, the contrast agent Endorem was injected i.v. and rBVol was determined using DCE-MRI followed by the WIN method for IFP both before (day 0) and after (day 2) treatment with vehicle or patupilone (4 mg/kg i.v. bolus once). Individual values from each tumor. Points, mean before and after treatment for (A) rBVol and (D) IFP; bars, SE. **, P = 0.0005; *, P = 0.02, compared with baseline (two-tailed paired t test). A rBVol map is shown for a representative lymph node tumor before (B) and after (C) patupilone treatment, where the change in rBVol was calculated to be −38%.

Close modal

In a separate cohort of mice, the IFP of established cervical metastases (>14 days old) was also examined before and 2 days after treatment with patupilone (4 mg/kg) or vehicle. Vehicle-treated mice showed no overall change in IFP (17 ± 15%), whereas patupilone-treated mice showed a significant decrease (P = 0.02) compared with baseline (−32 ± 16%; see Fig. 2D), and this was significantly different to the percentage change in the vehicle group (P = 0.042, two-tailed t test). Vascular casts from a separate cohort of mice showed a trend for patupilone to reduce the vascular index after 2 days: mean 8.4 ± 1.6% for five vehicle-treated mice and mean 5.5 ± 1.4% for six patupilone-treated mice (casts not shown).

Effect of 1.5 mg/kg patupilone treatment in the BN472 rat mammary carcinoma model. A single dose of patupilone was strongly efficacious against the mammary BN472 tumor transplanted orthotopically in rats. One week after treatment, there was little or no tumor growth (T/C, 10.4%), mild diarrhea in some rats, and full survival (8 of 8), but there was significant body weight loss (−22 ± 2%). The overall exposure in these rats (mg/m2) was similar to the high dose given to B16/BL6 mice (i.e., 9 and 14 mg/m2 for rats and mice, respectively).

The effect of this single dose of 1.5 mg/kg patupilone on the vascularity of BN472 mammary tumors was investigated noninvasively using DSC-MRI to determine absolute BVol and IFP in the same animals both before and 2 days after treatment with patupilone in comparison with vehicle treatment. Representative BVol maps are shown in Fig. 3. BVol was not significantly affected by vehicle treatment (27 ± 11%), but patupilone induced a significant decrease compared with baseline (P = 0.034, two-tailed paired t test) in 4 of 4 tumors (−42 ± 9%), and this was significantly different to the percentage change in the vehicle group (P = 0.026, two-tailed t test; Fig. 3E). The basal IFP ranged between 9 and 19 mm Hg and this was also not affected by vehicle treatment (21 ± 17%) but was significantly decreased (P = 0.011, two-tailed paired t test) by patupilone in 4 of 4 tumors compared with baseline (−50 ± 4%), and this was significantly different to the percentage change in the vehicle group (P = 0.029, two-tailed t test; Fig. 3F). These changes in BVol and IFP were very similar; indeed, the changes (Δ values) induced by patupilone in these two variables were significantly positively correlated (R = 1.0; P = 0.018). Thus, a lower IFP was associated with a lower BVol. Consistent with a decrease in BVol, vascular casts of BN472 tumors made 2 days after treatment showed a large decrease in the vascular volume compared with vehicle-treated rats of ∼40% (casts not shown).

Fig. 3.

Effect of 1.5 mg/kg patupilone on BVol and IFP of rat mammary BN472 tumors after 2 days. BN472 tumors were created by transplantation. After 3 weeks, the contrast agent Sinerem was injected i.v. and BVol was determined using DSC-MRI followed by the WIN method for IFP both before (day 0) and after (day 2) treatment with vehicle or patupilone (1.5 mg/kg i.v. bolus once). BVol maps for tumors before (A and C) and after (B and D) treatment with vehicle (A and B) or patupilone (C and D), where the changes in BVol were −11% and −67% for the vehicle-treated and patupilone-treated animals, respectively. Individual values from each tumor. Points, mean before and after treatment for (E) BVol and (F) IFP; bars, SE. *, P < 0.05, compared with baseline (two-tailed paired t test).

Fig. 3.

Effect of 1.5 mg/kg patupilone on BVol and IFP of rat mammary BN472 tumors after 2 days. BN472 tumors were created by transplantation. After 3 weeks, the contrast agent Sinerem was injected i.v. and BVol was determined using DSC-MRI followed by the WIN method for IFP both before (day 0) and after (day 2) treatment with vehicle or patupilone (1.5 mg/kg i.v. bolus once). BVol maps for tumors before (A and C) and after (B and D) treatment with vehicle (A and B) or patupilone (C and D), where the changes in BVol were −11% and −67% for the vehicle-treated and patupilone-treated animals, respectively. Individual values from each tumor. Points, mean before and after treatment for (E) BVol and (F) IFP; bars, SE. *, P < 0.05, compared with baseline (two-tailed paired t test).

Close modal

BN472 tumors: dose dependency of interstitial fluid pressure and volume changes and their correlation. Patupilone induced no changes in TVol after 2 days (data not shown), but after 6 days significant inhibition was apparent at doses of ≥0.8 mg/kg as indicated by the %T/C, and there was a dose-dependent effect on body weight (Table 1). For IFP, significant decreases in comparison with baseline were only recorded for the ≥0.8 mg/kg dose; in general, the decrease tended to be greater after 6 days than after 2 days. The 0.8 mg/kg dose seemed to provide the widest therapeutic index, inducing tumor regression, moderate body weight loss, and significant decreases in IFP of >50%. Vehicle-treated rats showed no significant change in IFP, although some individual tumors showed quite large increases or decreases (several cluster at −30% to −35%) as illustrated by Fig. 4 from the data shown in Table 1.

Table 1.

Dose-dependent effects of patupilone treatment on Brown-Norway rat body weight and BN472 TVol and IFP

Treatment (mg/kg)Tumor response
Host response
Δ%IFP (day 2)Δ%IFP (day 6)ΔTVol (days 6-0), mm3%T/CΔ%Body weight (day 2)Δ%Body weight (day 6)Survival (%)
Vehicle 5.2 ± 7.5 (23) 10.0 ± 9.5 (16) 1,830 ± 284 (21) — 1.2 ± 0.4 (23) 5.3 ± 0.5 (21) 91
0.3 −21.4 ± 10.6 (6) −28.1 ± 19.8 (5) 1,509 ± 470 (5) 82.5 0.3 ± 2.4 (6) −2.2 ± 4.1 (5) 80
0.8 −55.3 ± 5.9 (11)* −55.8 ± 4.2 (10)* −507 ± 65 (10) −26.2 −4.9 ± 0.8 (11) −10.3 ± 1.1 (10) 92
−45.2 ± 10.1 (6)* −69.6 ± 3 (4)* 417 ± 145 (4) 22.8 −5.6 ± 0.9 (6) −17.4 ± 2 (4) 67
1.5 −43.7 ± 5.8 (5)* −64.6 ± 3.5 (4)* 102 ± 108 (5) 5.6 −7.9 ± 0.4 (5) −25.9 ± 1.5 (5) 80
Treatment (mg/kg)Tumor response
Host response
Δ%IFP (day 2)Δ%IFP (day 6)ΔTVol (days 6-0), mm3%T/CΔ%Body weight (day 2)Δ%Body weight (day 6)Survival (%)
Vehicle 5.2 ± 7.5 (23) 10.0 ± 9.5 (16) 1,830 ± 284 (21) — 1.2 ± 0.4 (23) 5.3 ± 0.5 (21) 91
0.3 −21.4 ± 10.6 (6) −28.1 ± 19.8 (5) 1,509 ± 470 (5) 82.5 0.3 ± 2.4 (6) −2.2 ± 4.1 (5) 80
0.8 −55.3 ± 5.9 (11)* −55.8 ± 4.2 (10)* −507 ± 65 (10) −26.2 −4.9 ± 0.8 (11) −10.3 ± 1.1 (10) 92
−45.2 ± 10.1 (6)* −69.6 ± 3 (4)* 417 ± 145 (4) 22.8 −5.6 ± 0.9 (6) −17.4 ± 2 (4) 67
1.5 −43.7 ± 5.8 (5)* −64.6 ± 3.5 (4)* 102 ± 108 (5) 5.6 −7.9 ± 0.4 (5) −25.9 ± 1.5 (5) 80

NOTE: Rats bearing orthotopic mammary BN472 of at least 500 mm3 were investigated using the WIN technique to determine tumor IFP at baseline (day 0) and at days 2 and 6 following treatment with vehicle or the different single doses of patupilone. TVol and body weight were also recorded on these days. Data were collated from four different experiments [mean ± SE (n animals)].

*

P < 0.01, significantly different from baseline (one-way repeated measures ANOVA with Holms-Sidak post hoc).

P < 0.01, significantly different from the respective vehicle control (one-way ANOVA with Holms-Sidak post hoc).

Fig. 4.

Correlation between percentage change in IFP and change in volume of BN472 mammary tumors following treatment with different single doses of patupilone. BN472 tumors were created by transplantation and after 3 weeks were examined by the WIN method for IFP both before (day 0) and after (days 2 and 6) treatment with patupilone (0, 0.3, 0.8, 1.0, and 1.5 mg/kg i.v.). Data from in Table 1. A, Pearson correlation for individual tumors between Δ%IFP at day 2 and ΔTVol at day 6. B, Δ%IFP at day 2 and the tumor response, classified as nonresponder (NR) or responder (R), using −35% ΔIFP as a cutoff. Dotted line, mean for each group. P = 0.0002 (Fisher's exact test; see Statistical methods).

Fig. 4.

Correlation between percentage change in IFP and change in volume of BN472 mammary tumors following treatment with different single doses of patupilone. BN472 tumors were created by transplantation and after 3 weeks were examined by the WIN method for IFP both before (day 0) and after (days 2 and 6) treatment with patupilone (0, 0.3, 0.8, 1.0, and 1.5 mg/kg i.v.). Data from in Table 1. A, Pearson correlation for individual tumors between Δ%IFP at day 2 and ΔTVol at day 6. B, Δ%IFP at day 2 and the tumor response, classified as nonresponder (NR) or responder (R), using −35% ΔIFP as a cutoff. Dotted line, mean for each group. P = 0.0002 (Fisher's exact test; see Statistical methods).

Close modal

Figure 4A shows that the largest percentage decreases in IFP measured on day 2 (Δ%IFPday2-0) were associated with the greatest efficacy as determined by the change in TVol on day 6, and although there was considerable scatter, the two variables were significantly correlated (Pearson R = 0.42; P = 0.005). A similar correlation was observed for the Δ%IFPday6-0 (Pearson R = 0.42; P = 0.008). Thus, changes in IFP after just 2 days predicted changes in TVol (i.e., tumor response). Furthermore, there was a highly significant association (P = 0.0002, Fisher's exact test) between large decreases in IFP after 2 days and tumor response after 6 days (Fig. 4B). For any dose or all doses pooled, there was no evidence that the baseline IFP was correlated to the tumor response (data not shown).

BN472 tumors: changes in interstitial fluid pressure and volume and correlation with magnetic resonance measured vascularity and histology after 0.8 mg/kg patupilone. As reported above (Table 1), a 0.8 mg/kg dose caused a >50% decrease in IFP at days 2 and 6 (Fig. 5A) but a significant decrease in BVol (−50 ± 4%) was not detectable until day 6 (P < 0.001), Fig. 5B. Patupilone also caused by day 6 a significant decrease (P = 0.01) in the VSI (−40 ± 11%) from 16.0 ± 1 to 9.6 ± 2.1 μm (see Fig. 5C). However, tumor ADC, considered as a marker of apoptosis and/or necrosis, was unchanged by treatment with either vehicle or patupilone (Fig. 5D). Histologic analysis of these tumors on day 6 showed no significant change in necrosis was induced by patupilone, although there was a 2.4-fold increase in apoptosis, which was highly significant (P = 0.000006; see Fig. 5E-H). Thus, in this model, ADC did not reflect changes in apoptosis.

Fig. 5.

Effect of 0.8 mg/kg patupilone on the IFP, magnetic resonance–determined vascular variables, and histology of BN472 mammary tumors. BN472 tumors were created by transplantation and after 3 weeks examined by DCE-MRI for BVol, VSI, and ADC and the WIN method for IFP both before (day 0) and after (days 2 and 6) treatment with vehicle or patupilone (0.8 mg/kg i.v. bolus once). Animals were then sacrificed for measurement of apoptosis and necrosis. Individual values from each tumor. Points, mean for (A) IFP, (B) BVol, (C) VSI, (D) ADC, (E) apoptosis, and (F) necrosis; bars, SE. **, P < 0.001; *, P < 0.01 significantly different versus baseline (one-way repeated-measures ANOVA applying the Holms-Sidak post hoc). Also representative microphotographs of BN472 tumor sections displaying caspase-3 activity 6 days after treatment with vehicle (G) or patupilone (H). Magnification, ×400.

Fig. 5.

Effect of 0.8 mg/kg patupilone on the IFP, magnetic resonance–determined vascular variables, and histology of BN472 mammary tumors. BN472 tumors were created by transplantation and after 3 weeks examined by DCE-MRI for BVol, VSI, and ADC and the WIN method for IFP both before (day 0) and after (days 2 and 6) treatment with vehicle or patupilone (0.8 mg/kg i.v. bolus once). Animals were then sacrificed for measurement of apoptosis and necrosis. Individual values from each tumor. Points, mean for (A) IFP, (B) BVol, (C) VSI, (D) ADC, (E) apoptosis, and (F) necrosis; bars, SE. **, P < 0.001; *, P < 0.01 significantly different versus baseline (one-way repeated-measures ANOVA applying the Holms-Sidak post hoc). Also representative microphotographs of BN472 tumor sections displaying caspase-3 activity 6 days after treatment with vehicle (G) or patupilone (H). Magnification, ×400.

Close modal

For this subset of data (0 and 0.8 mg/kg), the percentage changes compared with baseline (day 0) observed in IFP (Δ%IFP) at days 2 and 6 were positively and significantly correlated with the change in TVol from days 0 to 6, Δ%IFPday2-0 (Pearson R = 0.49; P = 0.026; n = 21), and Δ%IFPday6-0 (Pearson R = 0.54; P = 0.012; n = 21). A similar correlation was observed for the Δ%VSIday6-0 (Pearson R = 0.49; P = 0.047; n = 17). The Δ%BVolday6-0 seemed not to be correlated with response, but this was due to one extreme outlier (Grubb's outlier test) in the vehicle group that had a low BVol on day 0 (1.1%) and showed a 400% increase by day 6. Removal of this single tumor revealed a strong positive correlation between BVol and tumor response (Pearson R = 0.7; P = 0.0014; n = 18).

Multiple correlations between the different variables confirmed that there was no significant correlation between ADC and apoptosis and nor with necrosis (P > 0.1). However, TVol, IFP, and BVol were strongly negatively correlated with apoptosis in individual tumors (P < 0.001; i.e., high apoptosis was associated with a small TVol and a low IFP and BVol; Fig. 6A and C). Strong positive correlations were observed between BVol and VSI (P = 0.0018), and these two variables were also strongly correlated with TVol (P = 0.0007 and 0.0023, respectively). Thus, larger tumors had a larger BVol with wider vessels. Finally, the BVol was also strongly positively correlated to IFP (P = 0.0005; see Fig. 6D), confirming observations described above at the 1.5 mg/kg dose. Four other pairs of variables also reached significance (P = 0.023-0.045) but not following a Bonferroni correction (P multiplied by number of correlations done; i.e., n = 21; data not shown).

Fig. 6.

Correlation between TVol, IFP, BVol, and apoptosis in BN472 mammary tumors following treatment with 0.8 mg/kg patupilone. Data from Fig. 4 and Table 1. Individual values for all treated tumors where all variables were measurable. Pearson correlation coefficients and associated P for each plot.

Fig. 6.

Correlation between TVol, IFP, BVol, and apoptosis in BN472 mammary tumors following treatment with 0.8 mg/kg patupilone. Data from Fig. 4 and Table 1. Individual values for all treated tumors where all variables were measurable. Pearson correlation coefficients and associated P for each plot.

Close modal

We have shown that patupilone was strongly efficacious (T/C, ≤20%) at tolerable doses in two different syngeneic orthotopic solid tumor rodent models, including the metastases. Other data, not reported herein but elsewhere (36), also showed significant activity (T/C, 0-39%) at tolerable doses (≤1.75 mg/kg i.v.) in another primary orthotopic rat mammary tumor, MTLn3, including the metastases, and also against established human HT1080 fibrosarcoma cells growing in the lungs of nude mice.

In the mouse B16/BL6 melanoma cervical metastases and the rat BN472 mammary tumor, several different variables relating to tumor vascularity were studied at 2 and/or 6 days after drug treatment and were compared with vehicle-treated animals. In both models, patupilone caused a rapid destruction of blood vessels before a significant change in TVol was detectable. This effect was measurable by ex vivo methods (e.g., histologic staining) and by plastic casts of blood vessels as well as in situ using MRI and by measuring tumor IFP. In BN472 tumors, the data showed that changes in IFP preceded and correlated with tumor response, suggesting this might be a useful clinical surrogate biomarker of a chemotherapeutic response to this drug.

Two weeks after treatment, histology showed that inhibition of growth of B16/BL6 metastases was associated with a significant decrease in blood vessel density (P = 0.014). The histology dye used stains functional vasculature and is therefore an ex vivo equivalent of the noninvasive DCE-MRI measurements of (relative) BVol. DCE-MRI measurements showed that after just 2 days patupilone significantly decreased the rBVol (P = 0.0005). Other vascular variables, such as vessel permeability and overall perfusion, were unaffected, a distinct difference in vascular response in comparison with therapies that target vascular endothelial growth factor (24, 37) or the vascular endothelial growth factor receptor (33) or the endothelial cells directly (38, 39) and not necessarily expected given that other antivascular/disruptive therapies can decrease permeability and/or perfusion (9, 40). Vascular casts of tumors made 2 days after treatment showed a trend for patupilone to induce a decrease in blood vessel mass, and at this time point, the tumor IFP was also decreased (P = 0.02). Thus, the large changes in blood vessel architecture measurable 2 weeks after patupilone treatment were already detectable after just 2 days by the noninvasive method and this was paralleled by a decrease in tumor IFP. Tumor IFP is raised for several reasons, but a major contributor is likely to be the chaotic blood supply (17, 18); thus, a destruction of blood vessels may lead to a reorganization that relieves some of the tumor pressure (41).

The relationship between tumor vasculature and IFP was further investigated in the rat BN472 tumors. Patupilone was efficacious against these tumors with significant changes in tumor size apparent 1 week after treatment. Two days after treatment with a dose of 1.5 mg/kg, large decreases of ∼50% in the BVol and IFP were detectable (P < 0.05) and the changes in these two variables correlated with each other (P = 0.018), suggesting that a low IFP was associated with a low BVol. Vascular casts, an ex vivo method, made at this time point and dose confirmed a trend for patupilone to decrease blood vessel mass.

Finally, also in the BN472 model, patupilone dose-dependently inhibited tumor growth and dose-dependently decreased the IFP. The Δ%IFP induced by the different doses of patupilone correlated significantly with the subsequent ΔTVol (P = 0.005) again well before a change in TVol was apparent. Hence, the dose-response data confirmed that Δ%IFP could be used to predict tumor response. Although others have shown that different drugs can decrease the IFP of solid tumors, including prostaglandin E1 (19), dexamethasone (21), imatinib (22), and paclitaxel (23), as far as we are aware, this is the first report showing that the decrease in IFP is directly related to tumor drug response. As hypothesized by Milosevic et al. (43), this drug-induced decrease in IFP may also be a factor in inhibiting subsequent metastases, as we found in three animal models.

In conclusion, the novel microtubule stabilizer, patupilone, at efficacious and tolerable doses, caused a rapid destruction of tumor blood vessels well before a significant change of TVol was apparent. In the rat mammary BN472 model, four potential biomarkers of response were measured in situ, and IFP seemed to be the best predictor of tumor response and also correlated positively with tumor vascularity and negatively with apoptosis. Hence, our observations confirmed that the raised IFP typical of solid tumors is related to blood vessel architecture and tumor cell density, and decreases in IFP may act therefore as a surrogate measure of destruction of tumor cells and blood vessels. In experimental tumors, IFP is relatively easy to measure and, provided the tumors are not very large, is independent of both tumor size and where the IFP is measured in the tumor. In the clinic, however, IFP is not routinely measured and would be expected to be limited to superficial tumors (43). This makes the MRI measurement of BVol attractive, but except for the brain (40, 44) it requires the use of exogenous contrast agents that have yet to be approved for oncology. Similarly, although many Annexin V probes are under development for noninvasive assessment of apoptosis, none have yet been approved for clinical use (45). Thus, our data suggest that measurement of tumor IFP in the clinic is desirable because drug-induced changes in IFP could be a useful surrogate biomarker of tumor response to treatment with patupilone and might even be used for patient stratification. Furthermore, decreases in IFP induced by patupilone or similar compounds may aid uptake of subsequent chemotherapy, including the epothilone itself (46), a strategy that should aid combination chemotherapy or alternative scheduling of monotherapy.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank T. Krucker and E. Meyer (Department of Neuropharmacology, Scripps Research Institute, La Jolla, CA) for showing the technology for making casts.

1
Hoefle G, Steinmetz H, Bedorf N, Schomberg D, Gerth K, Reichenbach H. Epothilone A and B—novel 16-membered macrolides with cytotoxic activity: isolation, crystal structure, and conformation in solution.
Angew Chem Int Ed Engl
1996
;
35
:
1567
–9.
2
Buey RM, Diaz JF, Andreu JM, et al. Interaction of epothilone analogs with the paclitaxel binding site: relationship between binding affinity, microtubule stabilization, and cytotoxicity.
Chem Biol
2004
;
11
:
225
–36.
3
Nettles JH, Li H, Cornett B, Krahn JM, Snyder JP, Downing KH. The binding mode of epothilone A on αβ-tubulin by electron crystallography.
Science
2004
;
305
:
866
–9.
4
Altmann KH, Wartmann M, O'Reilly T. Epothilones and related structures—a new class of microtubule inhibitors with potent in vivo antitumor activity.
Biochem Biophys Acta Rev Cancer
2000
;
1470
:
M79
–91.
5
Wartmann M, Altmann K-H. The Biology and Medicinal Chemistry of Epothilones.
Curr Med Chem Anti-Canc Agents
2002
;
2
:
123
–48.
6
Bollag DM, McQueney PA, Zhu J, et al. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action.
Cancer Res
1995
;
55
:
2325
–33.
7
Broker LE, Huisman C, Span SW, Rodriguez JA, Kruyt FA, Giaccone G. Cathepsin B mediates caspase-independent cell death induced by microtubule stabilizing agents in non-small cell lung cancer cells.
Cancer Res
2004
;
64
:
27
–30.
8
Giannakakou P, Sackett DL, Kang YK. Paclitaxel-resistant human ovarian cancer cells have mutant β-tubulins that exhibit impaired paclitaxel-driven polymerization.
J Biol Chem
1995
;
272
:
17118
–25.
9
Thorpe PE. Vascular targeting agents as cancer chemotherapeutics.
Clin Cancer Res
2004
;
10
:
415
–27.
10
Bocci G, Nicholaou KC, Kerbel RS. Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective anti-angiogenic window for various drugs.
Cancer Res
2002
;
62
:
6938
–43.
11
Woltering EA, Lewis JM, Maxwell PJ IV, et al. Development of a novel in vitro human tissue-based angiogenesis assay to evaluate the effect of antiangiogenic drugs.
Ann Surg
2003
;
237
:
790
–8.
12
Goodin S, Kane MP, Rubin EH. Epothilones: mechanism of action and biologic activity.
J Clin Oncol
2004
;
22
:
2015
–25.
13
Pietras K, Stumm M, Hubert M, et al. Imatinib enhances the therapeutic index of epothilone B (EPO906) by a tumor-selective increase of drug uptake.
Clin Cancer Res
2003
;
9
:
3779
–87.
14
Rothermel J, Wartmann M, Chen T, Hohneker J. EPO906 (epothilone B): a promising novel microtubule stabilizer.
Semin Oncol
2003
;
30
Suppl 6:
S51
–5.
15
Brueggen J, Altmann K-H, Blum W, et al. Pharmacokinetics of EPO906 (epothilone B) in HCT-15 tumor bearing mice. Proceedings of the 93rd AACR; San Francisco, CA; 2002 Apr 6-10. p. 212.
16
O'Reilly T, Wartmann M, Maira S-M, et al. Patupilone (epothilone B, EPO906) and imatinib (STI571, Glivec®) in combination display enhanced antitumor activity in vivo against experimental rat C6 glioma.
Cancer Chemother Pharmacol
2005
;
55
:
117
–28.
17
Jain RK. Barriers to drug deliver in solid tumors.
Sci Am
1994
;
271
:
58
–65.
18
Brown JM, Giaccia AJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy.
Cancer Res
1998
;
58
:
1408
–16.
19
Pietras K, Rubin K, Sjoblom T, et al. Inhibition of PDGF receptor signalling in tumor stroma enhances antitumor effect of chemotherapy.
Cancer Res
2002
;
62
:
5476
–84.
20
Salnikov AV, Iversen VV, Koisti M, et al. Lowering of tumor interstitial fluid pressure specifically augments efficacy of chemotherapy.
FASEB J
2003
;
17
:
1756
–8.
21
Kristjansen PE, Boucher Y, Jain RK. Dexamethasone reduces the interstitial fluid pressure in a human colon adenocarcinoma xenograft.
Cancer Res
1993
;
53
:
4764
–6.
22
Pietras K, Ostman A, Sjoquist M, et al. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors.
Cancer Res
2001
;
61
:
2929
–34.
23
Griffon-Etienne G, Boucher Y, Brekken C, Suit HD, Jain RK. Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications.
Cancer Res
1999
;
59
:
3776
–82.
24
Lee CG, Heijn M, di Tomaso E, et al. Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions.
Cancer Res
2000
;
60
:
5565
–70.
25
Milosevic M, Fyles A, Hedley D, et al. Interstitial fluid pressure predicts survival in patients with cervix cancer independent of clinical prognostic factors and tumor oxygen measurements.
Cancer Res
2001
;
61
:
6400
–5.
26
Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer.
Nat Med
2004
;
10
:
145
–7.
27
Taghian AG, Abi-Raad R, Assaad SI, et al. Paclitaxel decreases the interstitial fluid pressure and improves oxygenation in breast cancers in patients treated with neoadjuvant chemotherapy: clinical implications.
J Clin Oncol
2005
;
23
:
1951
–61.
28
Thiesse P, Ollivier L, Di Stefano-Louineau D, et al. Response rate accuracy in oncology trials: reasons for inter-observer variability.
J Clin Oncol
1997
;
15
:
3507
–14.
29
Stroobants S, Goeminne J, Seegers M, et al. 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec).
Eur J Cancer
2003
;
39
:
2012
–20.
30
Gronlund B, Hogdall C, Hilden J, Engelholm SA, Hogdall EV, Hansen HH. Should CA-125 response criteria be preferred to Response Evaluation Criteria in Solid Tumors (RECIST) for prognostication during second-line chemotherapy of ovarian carcinoma?
J Clin Oncol
2004
;
22
:
4051
–8.
31
Woude GF, Kelloff GJ, Ruddon RW, et al. Reanalysis of cancer drugs: old drugs, new tricks.
Cancer Res
2004
;
10
:
3897
–907.
32
Morgan B, Thomas AL, Drevs J, et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies.
J Clin Oncol
2003
;
21
:
3955
–64.
33
Rudin M, McSheehy PMJ, Allegrini PR, et al. PTK787/ZK222584, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor, reduces uptake of the contrast agent GdDOTA by murine orthotopic B16/BL6 melanoma tumors and inhibits their growth in vivo.
NMR Biomed
2005
;
18
:
308
–21.
34
Dennie J, Mandeville JB, Boxerman JL, Packard SD, Rosen BR, Weisskoff RM. NMR imaging of changes in vascular morphology due to tumor angiogenesis.
Magn Reson Med
1998
;
40
:
793
–9.
35
Troprès I, Grimault S, Vaeth A, et al. Vessel size imaging.
Magn Reson Med
2001
;
45
:
397
–408.
36
McSheehy PMJ, Schnell C, Ferretti S, Allegrini PR, Wartmann M, Wood J. Epothilone B (EPO906) demonstrates anti-angiogenic and anti-metastatic activity in syngeneic rodent tumor models. Proceedings of the 94th AACR; Washington, DC; 2003 Jul 11-14. p. 538.
37
Preda A, Novikov V, Moglich M, et al. MRI monitoring of Avastin antiangiogenesis therapy using B22956/1, a new blood pool contrast agent, in an experimental model of human cancer.
J Magn Reson Imaging
2004
;
20
:
865
–73.
38
Maxwell RJ, Wilson J, Prise VE, et al. Evaluation of the anti-vascular effects of combretastatin in rodent tumors by dynamic contrast enhanced MRI.
NMR Biomed
2002
;
15
:
89
–98.
39
Robinson SP, McIntyre DJO, Checkley D, et al. Tumor dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging.
Br J Cancer
2003
;
88
:
1592
–7.
40
Leach MO, Brindle KM, Evelhoch JL, et al. The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations.
Br J Cancer
2005
;
92
:
1599
–610.
41
Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy.
Nat Med
2001
;
7
:
987
–9.
42
Kauppinen RA. Monitoring cytotoxic tumor treatment response by diffusion magnetic resonance imaging and proton spectroscopy.
NMR Biomed
2002
;
15
:
6
–17.
43
Milosevic M, Fyles A, Hedley D, Hill R. The human tumor microenvironment: invasive (needle) measurement of oxygen and interstitial fluid pressure.
2004
;
14
:
249
–58.
44
Rees J. Advances in magnetic resonance imaging of brain tumours.
Curr Opin Neurol
2003
;
16
:
643
–50.
45
Lahorte CM, Vanderheyden JL, Steinmetz N, Van de Wiele C, Dierckx RA, Slegers G. Apoptosis-detecting radioligands: current state of the art and future perspectives.
Eur J Nucl Med Mol Imaging
2004
;
31
:
887
–919.
46
McSheehy PMJ, Becquet M, Ferretti S, Brueggen J, Schweitzer A, Wartmann M. Optimisation of a pre-clinical dosing schedule for the novel epothilone analogue ABJ879 based on tumour interstitial fluid pressure modulation in rat mammary tumour models [abstract 526]. Proceedings of the 16th Symposium on Molecular Targets and Cancer Therapeutics; Geneva, Switzerland; 2004 Sep 28-Oct 1.